Future therapeutics for the induction of peripheral immune tolerance in autoimmune disease and organ transplantation

Immunotherapy

Volumn 1, Issue 3, 2009, Pages 447-460

  Cobbold, Stephen P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Antibody therapy; Autoimmune disease; Dendritic cell; Foxp3; Immune privilege; Mouse model; Regulatory T cell; TGF ; Tolerance; Transplantation

Indexed keywords

ACEBUTOLOL; ALEMTUZUMAB; CD2 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CD40 LIGAND; CD45RA ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPITOPE; GLATIRAMER; HEME OXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 22; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OKT 3; TRANSFORMING GROWTH FACTOR BETA; TRYPTOPHAN;

AUTOIMMUNE DISEASE; CD4+ CD25+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HEMOSTASIS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH2 CELL;

ANIMALS; AUTOIMMUNE DISEASES; CELL COMMUNICATION; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MICE; ORGAN TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY;

EID: 77953365066     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.09.9     Document Type: Review

References (138)

1. Benjamin RJ, Cobbold SP, Clark MR, Waldmann H: Tolerance to rat monoclonal antibodies. Implications for serotherapy. J. Exp. Med. 163(6), 1539-1552 (1986).
2. Billingham RE, Brent L, Medawar PB: Actively acquired tolerance of foreign cells. Nature 172(4379), 603-606 (1953).
3. Molleston JP, Alevy YG, SivaSai KS, Mohanakumar T, Howard TK: Evidence that pediatric liver transplant recipients may undergo late rejection episodes in spite of donor-specific microchimerism. Transplantation 61(4), 656-657 (1996). (Pubitemid 26073616)
4. Wekerle T, Kurtz J, Ito H et al.: Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat. Med. 6(4), 464-469 (2000).
5. Fehr T, Sykes M: Clinical experience with mixed chimerism to induce transplantation tolerance. Transpl. Int. 21(12), 1118-1135 (2008).
6. Benjamin RJ, Qin SX, Wise MP, Cobbold SP, Waldmann H: Mechanisms of monoclonal antibody-facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFA-1) molecules in self-non-self discrimination. Eur. J. Immunol. 18(7), 1079-1088 (1988).
7. + cells. J. Immunol. 137(11), 3414-3419 (1986).
8. Winsor-Hines D, Merrill C, O'Mahony M et al.: Induction of immunological tolerance/hyporesponsiveness in baboons with a nondepleting CD4 antibody. J. Immunol. 173(7), 4715-4723 (2004). ■ Demonstrates that the principles of monoclonal antibody-induced tolerance learned in rodent models can be successfully extended to primates.
9. Cobbold SP, Adams E, Marshall SE, Davies JD, Waldmann H: Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Immunol. Rev. 149, 5-33 (1996).
10. Waldmann H, Hale G, Cobbold S: Appropriate targets for monoclonal antibodies in the induction of transplantation tolerance. Philos. Trans. R. Soc. Lond. B. Biol. Sci 356(1409), 659-663 (2001).
11. Gershon RK, Kondo K: Infectious immunological tolerance. Immunology 21(6), 903-914 (1971).
12. Qin S, Cobbold SP, Pope H et al.: 'Infectious' transplantation tolerance. Science 259(5097), 974-977 (1993).
13. Davies JD, Leong LY, Mellor A, Cobbold SP, Waldmann H: T cell suppression in transplantation tolerance through linked recognition. J. Immunol. 156(10), 3602-3607 (1996). (Pubitemid 26137645)
14. Anderton SM, Wraith DC: Hierarchy in the ability of T cell epitopes to induce peripheral tolerance to antigens from myelin. Eur. J. Immunol. 28(4), 1251-1261 (1998).
15. Cobbold SP, Nolan KF, Graca L et al.: Regulatory T cells and dendritic cells in transplantation tolerance: molecular markers and mechanisms. Immunol. Rev. 196, 109-124 (2003).
16. Cobbold SP, Adams E, Graca L et al.: Immune privilege induced by regulatory T cells in transplantation tolerance. Immunol. Rev. 213, 239-255 (2006).
17. Sakaguchi S, Toda M, Asano M et al.: T cell-mediated maintenance of natural self-tolerance: its breakdown as a possible cause of various autoimmune diseases. J. Autoimmun. 9(2), 211-220 (1996). (Pubitemid 26163865)
18. + regulatory T cells induced by an agonist self-peptide. Nat. Immunol. 2(4), 301-306 (2001).
19. + regulatory T cells. J. Immunol. 168(4), 1644-1648 (2002). (Pubitemid 34135759)
20. + T regulatory cells. Nat. Immunol. 4(4), 337-342 (2003).
21. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor foxp3. Science 299(5609), 1057-1061 (2003). (Pubitemid 36222930)
22. + regulatory T cells. Nat. Immunol. 4(4), 330-336 (2003).
23. Chatenoud L, Salomon B, Bluestone JA: Suppressor T cells - they're back and critical for regulation of autoimmunity! Immunol. Rev. 182, 149-163 (2001). (Pubitemid 33070215)
24. + T cells. Proc. Natl Acad. Sci. USA 101(27), 10122-10126 (2004).
25. + T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J. Exp. Med. 197(1), 111-119 (2003).
26. + suppressor T cells in vivo. Nat. Immunol. 3(1), 33-41 (2002).
27. + T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J. Immunol. 166(5), 3008-3018 (2001). (Pubitemid 33117296)
28. - regulatory cells mediate dominant transplantation tolerance. J. Immunol. 168(11), 5558-5565 (2002). (Pubitemid 34556135)
29. Graca L, Cobbold SP, Waldmann H: Identification of regulatory T cells in tolerated allografts. J. Exp. Med. 195(12), 1641-1646 (2002).
30. + T cells or B cells. J. Immunol. 161(4), 1868-1874 (1998).
31. Robertson NJ, Chai JG, Millrain M et al.: Natural regulation of immunity to minor histocompatibility antigens. J. Immunol. 178(6), 3558-3565 (2007). (Pubitemid 46417622)
32. + T cells on the fate of allografts in the absence of immunosuppression. Transplantation 79(6), 648-654 (2005).
33. + regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J. Immunol. 172(10), 6003-6010 (2004). (Pubitemid 38621201)
34. Singh B, Read S, Asseman C et al.: Control of intestinal inflammation by regulatory T cells. Immunol. Rev. 182, 190-200 (2001).
35. Bommireddy R, Pathak LJ, Martin J et al.: Self-antigen recognition by TGF β1-deficient T cells causes their activation and systemic inflammation. Lab. Invest. 86(10), 1008-1019 (2006).
36. Shull MM, Ormsby I, Kier AB et al.: Targeted disruption of the mouse transforming growth factor-β 1 gene results in multifocal inflammatory disease. Nature 359(6397), 693-699 (1992).
37. Taylor AW, Alard P, Yee DG, Streilein JW: Aqueous humor induces transforming growth factor-β (TGF-β)-producing regulatory T-cells. Curr Eye Res 16(9), 900-908 (1997).
38. + T cells are required for suppressor cell production and immune privilege in the anterior chamber of the eye. Immunology 110(1), 18-29 (2003).
39. Belghith M, Bluestone JA, Barriot S et al.: TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 9(9), 1202-1208 (2003).
40. + regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice. Proc. Natl Acad. Sci. USA 101(Suppl. 2), 14580-14585 (2004).
41. + regulatory T cells is mediated by cell surface-bound transforming growth factor β. J. Exp. Med. 194(5), 629-644 (2001).
42. high-induced colitis by a TGF-β-dependent mechanism. J. Immunol. 170(5), 2516-2522 (2003). (Pubitemid 36245641)
43. - precursors. Am. J. Transplant 4(10), 1614-1627 (2004).
44. Tonkin DR, He J, Barbour G, Haskins K: Regulatory T cells prevent transfer of Type 1 diabetes in NOD mice only when their antigen is present in vivo. J. Immunol. 181(7), 4516-4522 (2008). ■ Confirms that self-tolerance requires the continued presence of antigen to maintain regulatory T cell activity.
45. + regulatory T lymphocytes through the induction of anergy and infectious tolerance. J. Immunol. 180(5), 2830-2838 (2008).
46. Aricha R, Feferman T, Fuchs S, Souroujon MC: Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis. J. Immunol. 180(4), 2132-2139 (2008).
47. + regulatory T cells by TGF-β induction of transcription factor FoxP3. J. Exp. Med. 198(12), 1875-1886 (2003).
48. - T cells to acquire regulatory cell function. Blood 101(12), 5076-5083 (2003). (Pubitemid 36857776)
49. Liang SC, Tan XY, Luxenberg DP et al.: Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203(10), 2271-2279 (2006).
50. Bettelli E, Carrier Y, Gao W et al.: Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 441(7090), 235-238 (2006).
51. + T helper cells. Cell 126(6), 1121-1133 (2006). (Pubitemid 44380299)
52. Mucida D, Park Y, Kim G et al.: Reciprocal Th17 and regulatory T cell differentiation mediated by retinoic acid. Science 317(5835), 256-260 (2007). (Pubitemid 47076203)
53. + regulatory T cells via a TGF-β and retinoic acid-dependent mechanism. J. Exp. Med. 204(8), 1757-1764 (2007).
54. Rohn TA, Jennings GT, Hernandez M et al.: Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur. J. Immunol. 36(11), 2857-2867 (2006).
55. Izcue A, Hue S, Buonocore S et al.: Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 28(4), 559-570 (2008).
56. Elson CO, Cong Y, Weaver CT et al.: Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 132(7), 2359-2370 (2007). (Pubitemid 46890867)
57. + Tregs are not a stable phenotype and may be induced to become autoimmune effector cells by further exposure to IL-6. Raises the possibility that Treg cells may be unable to control Th17-effector responses in some circumstances.
58. +17 equal rejection? Transplantation 84(9), 1071-1074 (2007).
59. Yuan X, Paez-Cortez J, Schmitt-Knosalla I et al.: A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J. Exp. Med. 205(13), 3133-3144 (2008).
60. Linsley PS, Greene JL, Tan P et al.: Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J. Exp. Med. 176(6), 1595-1604 (1992).
61. Salomon BBluestone JA: Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19, 225-252 (2001).
62. Mellor AL, Baban B, Chandler P et al.: Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 171(4), 1652-1655 (2003). (Pubitemid 36966447)
63. Larsen CP, Pearson TC, Adams AB et al.: Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA-4-Ig with potent immunosuppressive properties. Am. J. Transplant 5(3), 443-453 (2005).
64. Adams AB, Williams MA, Jones TR et al.: Heterologous immunity provides a potent barrier to transplantation tolerance. J. Clin. Invest. 111(12), 1887-1895 (2003).
65. + T cells and is overcome by IL-2. Eur. J. Immunol. 32(3), 634-643 (2002).
66. Ishida Y, Agata Y, Shibahara K, Honjo T: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11(11), 3887-3895 (1992).
67. Latchman Y, Wood CR, Chernova T et al.: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2(3), 261-268 (2001).
68. Sandner SE, Clarkson MR, Salama AD et al.: Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J. Immunol. 174(6), 3408-3415 (2005).
69. Ito T, Ueno T, Clarkson MR et al.: Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J. Immunol. 174(11), 6648-6656 (2005). (Pubitemid 40705625)
70. Barber DL, Wherry EJ, Masopust D et al.: Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077), 682-687 (2006). (Pubitemid 43237609)
71. Petroff MG, Chen L, Phillips TA et al.: B7 family molecules are favorably positioned at the human maternal-fetal interface. Biol. Reprod. 68(5), 1496-1504 (2003).
72. Guleria I, Khosroshahi A, Ansari MJ et al.: A critical role for the programmed death ligand 1 in fetomaternal tolerance. J. Exp. Med. 202(2), 231-237 (2005). ■ Demonstrates the importance of negative costimulation in the maintenance of a 'natural' form of transplantation tolerance against paternal antigens in the fetus.
73. Lee GK, Park HJ, Macleod M et al.: Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 107(4), 452-460 (2002).
74. Terness P, Bauer TM, Rose L et al.: Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196(4), 447-457 (2002).
75. Munn DH, Zhou M, Attwood JT et al.: Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281(5380), 1191-1193 (1998). (Pubitemid 28406294)
76. Aluvihare VR, Kallikourdis M, Betz AG: Regulatory T cells mediate maternal tolerance to the fetus. Nat. Immunol. 5(3), 266-271 (2004).
77. + regulatory cells that control intestinal inflammation. J. Exp. Med. 192(2), 295-302 (2000).
78. Zelenika D, Adams E, Humm S et al.: Regulatory T cells overexpress a subset of Th2 gene transcripts. J. Immunol. 168(3), 1069-1079 (2002). (Pubitemid 34094470)
79. Mellor AL, Chandler P, Baban B et al.: Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int. Immunol. 16(10), 1391-1401 (2004).
80. Parker DC, Greiner DL, Phillips NE et al.: Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc. Natl Acad. Sci. USA 92(21), 9560-9564 (1995).
81. + T cell tolerance and linked suppression. J. Immunol. 163(9), 4805-4810 (1999).
82. Kirk AD, Harlan DM, Armstrong NN et al.: CTLA-4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl Acad. Sci. USA 94(16), 8789-8794 (1997).
83. Shen XD, Ke B, Zhai Y et al.: CD154-CD40 T-cell costimulation pathway is required in the mechanism of hepatic ischemia/reperfusion injury, and its blockade facilitates and depends on heme oxygenase-1 mediated cytoprotection. Transplantation 74(3), 315-319 (2002). (Pubitemid 34894279)
84. Hancock WW, Buelow R, Sayegh MH, Turka LA: Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat. Med. 4(12), 1392-1396 (1998).
85. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB: Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat. Med. 6(2), 114 (2000).
86. Koyama I, Kawai T, Andrews D et al.: Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. Transplantation 77(3), 460-462 (2004). (Pubitemid 38209752)
87. Daley SR, Cobbold SP, Waldmann H: Fc-disabled anti-mouse CD40L antibodies retain efficacy in promoting transplantation tolerance. Am. J. Transplant 8(11), 2265-2271 (2008).
88. Kapturczak MH, Wasserfall C, Brusko T et al.: Heme oxygenase-1 modulates early inflammatory responses: evidence from the heme oxygenase-1-deficient mouse. Am. J. Pathol. 165(3), 1045-1053 (2004).
89. Nagy E, Jeney V, Yachie A et al.: Oxidation of hemoglobin by lipid hydroperoxide associated with low-density lipoprotein (LDL) and increased cytotoxic effect by LDL oxidation in heme oxygenase-1 (HO-1) deficiency. Cell Mol. Biol. (Noisy-le-grand) 51(4), 377-385 (2005).
90. + regulatory T cells. J. Immunol. 174(9), 5181-5186 (2005). (Pubitemid 40593154)
91. Pae HO, Oh GS, Choi BM et al.: Carbon monoxide produced by heme oxygenase-1 suppresses T cell proliferation via inhibition of IL-2 production. J. Immunol. 172(8), 4744-4751 (2004).
92. Hegazi RA, Rao KN, Mayle A et al.: Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathway. J. Exp. Med. 202(12), 1703-1713 (2005).
93. Datta PK, Koukouritaki SB, Hopp KA, Lianos EA: Heme oxygenase-1 induction attenuates inducible nitric oxide synthase expression and proteinuria in glomerulonephritis. J. Am. Soc. Nephrol. 10(12), 2540-2550 (1999).
94. Liu LM, MacPherson GG: Antigen acquisition by dendritic cells: intestinal dendritic cells acquire antigen administered orally and can prime naive T cells in vivo. J. Exp. Med. 177(5), 1299-1307 (1993).
95. Huang FP, MacPherson GG: Continuing education of the immune system -dendritic cells, immune regulation and tolerance. Curr. Mol. Med. 1(4), 457-468 (2001).
96. Goerdt S, Orfanos CE: Other functions, other genes: alternative activation of antigen-presenting cells. Immunity 10(2), 137-142 (1999). (Pubitemid 29115619)
97. Nestle FO, Farkas A, Conrad C: Dendritic-cell-based therapeutic vaccination against cancer. Curr. Opin. Immunol. 17(2), 163-169 (2005).
98. Jonuleit H, Schmitt E, Steinbrink K, Enk AH: Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol. 22(7), 394-400 (2001). (Pubitemid 32673646)
99. Gregori S, Casorati M, Amuchastegui S et al.: Regulatory T cells induced by 1 α,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol. 167(4), 1945-1953 (2001).
100. Sato K, Yamashita N, Baba M, Matsuyama T: Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood 101(9), 3581-3589 (2003). (Pubitemid 36857945)
101. Strobl H, Knapp W: TGF-β1 regulation of dendritic cells. Microbes Infect. 1(15), 1283-1290 (1999).
102. Nolan KF, Strong V, Soler D et al.: IL-10-conditioned dendritic cells, decommissioned for recruitment of adaptive immunity, elicit innate inflammatory gene products in response to danger signals. J. Immunol. 172(4), 2201-2209 (2004). (Pubitemid 38182367)
103. + T cells resulting in a failure to lyse tumor cells. Blood 93(5), 1634-1642 (1999).
104. Chorny A, Gonzalez-Rey E, Fernandez-Martin A, Ganea D, Delgado M: Vasoactive intestinal peptide induces regulatory dendritic cells that can prevent acute graft-versus-host disease while maintain graft-versus-tumor. Blood (2006).
105. Hackstein H, Morelli AE, Larregina AT et al.: Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J. Immunol. 166(12), 7053-7062 (2001). (Pubitemid 32525574)
106. Roelen DL, Schuurhuis DH, van den Boogaardt DE et al.: Prolongation of skin graft survival by modulation of the alloimmune response with alternatively activated dendritic cells. Transplantation 76(11), 1608-1615 (2003).
107. Pedersen AE, Gad M, Walter MR, Claesson MH: Induction of regulatory dendritic cells by dexamethasone and 1α,25-dihydroxyvitamin D(3). Immunol. Lett. 91(1), 63-69 (2004).
108. Yates SF, Paterson AM, Nolan KF et al.: Induction of regulatory T cells and dominant tolerance by dendritic cells incapable of full activation. J. Immunol. 179(2), 967-976 (2007).
109. Ehser S, Chuang JJ, Kleist C et al.: Suppressive dendritic cells as a tool for controlling allograft rejection in organ transplantation: promises and difficulties. Hum. Immunol. 69(3), 165-173 (2008).
110. Vanclee A, Schouten HC, Bos GM: Murine dendritic cells that are resistant to maturation are unable to induce tolerance to allogeneic stem cells. Transpl. Immunol. 16(1), 8-13 (2006).
111. Lee JW, Epardaud M, Sun J et al.: Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self. Nat. Immunol. 8(2), 181-190 (2007).
112. Wu Z, Bensinger SJ, Zhang J et al.: Homeostatic proliferation is a barrier to transplantation tolerance. Nat. Med. 10(1), 87-92 (2004).
113. Neujahr D, Chen C, Huang X et al.: Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J. Immunol. 176(8), 4632-4639 (2006). ■ Investigates mechanisms and possible solutions to one of the additional barriers to translating mouse therapeutic tolerance models into the clinic.
114. Cosimi AB, Burton RC, Colvin RB et al.: Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32(6), 535-539 (1981).
115. Tax WJ, Tamboer WP, Jacobs CW, Frenken LA, Koene RA: Role of polymorphic Fc receptor Fc γRIIa in cytokine release and adverse effects of murine IgG1 anti-CD3/T cell receptor antibody (WT31). Transplantation 63(1), 106-112 (1997).
116. Calne R, Friend P, Moffatt S et al.: Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 351(9117), 1701-1702 (1998). (Pubitemid 28254534)
117. Coles AJ, Compston DA, Selmaj KW et al.: Alemtuzumab vs interferon β-1a in early multiple sclerosis. N. Engl. J. Med. 359(17), 1786 - 1801 (2008). ■■ First clinical study to successfully use a brief lymphocyte-depleting antibody treatment to achieve long-term remissions, and even some reversal of disability, in chronic relapsing multiple sclerosis.
118. Cox AL, Thompson SA, Jones JL et al.: Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur. J. Immunol. 35(11), 3332-3342 (2005).
119. + regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am. J. Transplant 8(4), 793-802 (2008).
120. Isaacs JD, Burrows N, Wing M et al.: Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease. Clin. Exp. Immunol. 110(2), 158-166 (1997).
121. Chatenoud L, Primo J, Bach JF: CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J. Immunol. 158(6), 2947-2954 (1997). (Pubitemid 127470558)
122. Chatenoud L, Thervet E, Primo J, Bach JF: Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl Acad. Sci. USA 91(1), 123-127 (1994).
123. Herold KC, Gitelman SE, Masharani U et al.: A single course of anti-CD3 monoclonal antibody hOKT3γ1 (Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of Type 1 diabetes. Diabetes 51(6), 1763-1769 (2005). ■■ One of two similar clinical studies where a brief treatment has been successfully tested with the aim of achieving a long-term remission of an active autoimmune disease, based on the observations of tolerance induction in the rodent models. (Pubitemid 40770766)
124. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al.: Insulin needs after CD3-antibody therapy in new-onset Type 1 diabetes. N. Engl. J. Med. 352(25), 2598-2608 (2005). ■■ One of two similar clinical studies where a brief treatment has been successfully tested with the aim of achieving a long-term remission of an active autoimmune disease, based on the observations of tolerance induction in the rodent models.
125. Suntharalingam G, Perry MR, Ward S et al.: Cytokine storm in a Phase I trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355(10), 1018-1028 (2006).
126. Sloan-Lancaster J, Evavold BD, Allen PM: Th2 cell clonal anergy as a consequence of partial activation. J. Exp. Med. 180(4), 1195-1205 (1994).
127. Chen TC, Waldmann H, Fairchild PJ: Induction of dominant transplantation tolerance by an altered peptide ligand of the male antigen Dby. J. Clin. Invest. 113(12), 1754-1762 (2004).
128. Brocke S, Gijbels K, Allegretta M et al.: Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 379(6563), 343-346 (1996). (Pubitemid 126554845)
129. Kappos L, Comi G, Panitch H et al.: Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized Phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat. Med. 6(10), 1176-1182 (2000).
130. Bielekova B, Goodwin B, Richert N et al.: Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a Phase II clinical trial with an altered peptide ligand. Nat. Med. 6(10), 1167-1175 (2000).
131. Johnson KP, Brooks BR, Cohen JA et al.: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45(7), 1268-1276 (1995).
132. + regulatory T cells for cellular immunotherapy in patients with graft-versus-host disease. J. Immunother. 29(3), 336-349 (2006).
133. + regulatory T cells with indirect allospecificity to promote donor-specific transplantation tolerance. Transplant Proc. 38(10), 3199-3201 (2006). (Pubitemid 44908510)
134. + regulatory T cells promote experimental transplantation tolerance. Blood 109(2), 827-835 (2007).
135. + immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. J. Immunol. 176(2), 1266-1273 (2006). (Pubitemid 43099732)
136. Putnam AL, Brusko TM, Lee MR et al.: Expansion of human regulatory T cells from patients with Type 1 diabetes. Diabetes (2008).
137. + T-regulatory cells: toward therapy for human diseases. Immunol. Rev. 223, 391-421 (2008).
138. Morelli AE, Thomson AW: Tolerogenic dendritic cells and the quest for transplant tolerance. Nat. Rev. Immunol. 7(8), 610-621 (2007).